ERB-196
| ERB-196 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1345970-38-0 |
| PubChem | 118796 |
| DrugBank | |
| ChemSpider | 106207 |
| KEGG | |
ERB-196 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It was developed for potential therapeutic use, particularly in the treatment of pain and inflammation.
Chemical Structure[edit]
ERB-196 belongs to the class of tetrahydrocannabinol (THC) analogs. Its chemical structure is characterized by a dibenzopyran ring system with a 1,1-dimethylheptyl side chain. The IUPAC name for ERB-196 is (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol.
Pharmacology[edit]
ERB-196 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain sensation, appetite, and immune response.
Potential Therapeutic Uses[edit]
Research into ERB-196 has primarily focused on its potential applications in the treatment of chronic pain, neuropathic pain, and inflammatory diseases. Its high affinity for cannabinoid receptors suggests it could be effective in modulating pain and inflammation.
Legal Status[edit]
The legal status of ERB-196 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its similarity to other synthetic cannabinoids.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
